Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

被引：8

作者：

Ciccarese, Chiara ^{[1
]}

Montironi, Rodolfo ^{[2
]}

Fiorentino, Michelangelo ^{[3
]}

Martignoni, Guido ^{[4
,5
]}

Brunelli, Matteo ^{[4
]}

Iacovelli, Roberto ^{[1
]}

Lopez-Beltran, Antonio ^{[6
,7
]}

Cheng, Liang ^{[8
]}

Scarpelli, Marina ^{[2
]}

Moch, Holger ^{[9
]}

Tortora, Giampaolo ^{[1
]}

Massari, Francesco ^{[10
]}

机构：

[1] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, Verona, Italy

[2] Polytech Univ Marche Reg, Sch Med, AOU Osped Riuniti, Sect Pathol Anat, Ancona, Italy

[3] St Orsola Marcello Malpighi Hosp, Addarii Inst Oncol, Pathol Serv, Bologna, Italy

[4] Univ Verona, AOUI, Dept Pathol & Diagnost, Verona, Italy

[5] Pederzoli Hosp, Anat Pathol, Verona, Italy

[6] Univ Cordoba, Med Sch, Dept Surg & Pathol, Cordoba, Spain

[7] Champalimaud Clin Ctr, Lisbon, Portugal

[8] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA

[9] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, Zurich, Switzerland

[10] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy

来源：

CURRENT DRUG METABOLISM | 2017年 / 18卷 / 08期

关键词：

Prostate cancer; mCRPC; circulating tumor cells; CTCs; biomarker; malignancy; INCREASED SURVIVAL; PERIPHERAL-BLOOD; ABIRATERONE; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PREDNISONE; AMPLIFICATION; COUNTS; MARKER;

D O I：

10.2174/1389200218666170518163549

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Background: Prostate cancer is a common malignancy with highly molecular heterogeneity responsible for a wide spectrum of clinical behavior. To date, several treatment options are available, whose selection is currently based mainly on clinical criteria. Given the weakness of conventional imaging and PSA assay, the identification of a prognostic and predictive biomarker for choosing the appropriate treatment and monitoring its efficacy is a very topical issue in prostate cancer management. Circulating tumor cells (CTCs) have substantial promise for early tumor diagnosis, disease recurrence and metastatic spread monitoring as well as for biological tumor characterization, thus representing a reliable translational real-time biomarkers of prostate cancer. Conclusion: This paper summarized the main data available about CTCs detection, their prognostic value, and their potential predictive role for metastatic prostate cancer patients management.

引用

页码：692 / 699

页数：8

共 50 条

[21] Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors
Ali, Amina
Furusato, Bungo
Ts'o, Paul O. P.
Lum, Zhao-Ping
Elsamanoudi, Sally
Mohamed, Ahmed
Srivastava, Shiv
Moul, Judd W.
Brassell, Stephen A.
Sesterhenn, Isabell A.
McLeod, David G.
PATHOLOGY INTERNATIONAL, 2010, 60 (10) : 667 - 672
[22] Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study
Koinis, Filippos
Zafeiriou, Zafeiris
Messaritakis, Ippokratis
Katsaounis, Panagiotis
Koumarianou, Anna
Kontopodis, Emmanouil
Chantzara, Evangelia
Aidarinis, Chrissovalantis
Lazarou, Alexandros
Christodoulopoulos, George
Emmanouilides, Christos
Hatzidaki, Dora
Kallergi, Galatea
Georgoulias, Vassilis
Kotsakis, Athanasios
CANCERS, 2023, 15 (18)
[23] Plastin 3 expression in circulating tumor cells as a predictor of cancer status in patients with prostate cancer
Shih, Meng-Hung
Cha, Tai-Lung
Wu, Sheng-Tang
Meng, En
Tsao, Chih-Wei
Kao, Chien-Chang
Chen, Chin-Li
Juho, Yu-Ching
Ting, Hui-Kung
Sun, Guang-Huan
Chang, Sun-Yran
Yu, Dah-Shyong
Yang, Ming-Hsin
FORMOSAN JOURNAL OF SURGERY, 2025, 58 (01) : 1 - 5
[24] Applications of circulating tumor cells for prostate cancer
Cheng, Shirley
Chen, Jie-Fu
Lu, Yi-Tsung
Chung, Leland W. K.
Tseng, Hsian-Rong
Posadas, Edwin M.
ASIAN JOURNAL OF UROLOGY, 2016, 3 (04) : 254 - 259
[25] Detection of circulating tumor cells in different stages of prostate cancer
Mark Thalgott
Brigitte Rack
Tobias Maurer
Michael Souvatzoglou
Matthias Eiber
Veronika Kreß
Matthias M. Heck
Ulrich Andergassen
Roman Nawroth
Jürgen E. Gschwend
Margitta Retz
Journal of Cancer Research and Clinical Oncology, 2013, 139 : 755 - 763
[26] Biosensors for circulating tumor cells (CTCs)-biomarker detection in lung and prostate cancer: Trends and prospects
Hussain, Syed Harris
Huertas, Cesar S.
Mitchell, Arnan
Deman, Anne-Laure
Laurenceau, Emmanuelle
BIOSENSORS & BIOELECTRONICS, 2022, 197
[27] Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer
Wei, Tao
Zhang, Xiaoyu
Zhang, Qi
Yang, Jiaqi
Chen, Qi
Wang, Jianxin
Li, Xiang
Chen, Junye
Ma, Tao
Li, Guogang
Gao, Shunliang
Lou, Jianying
Que, Risheng
Wang, Yi
Dang, Xiaowei
Zheng, Lei
Liang, Tingbo
Bai, Xueli
CANCER LETTERS, 2019, 452 : 237 - 243
[28] Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer
Graf, Ryon P.
Hullings, Melanie
Barnett, Ethan S.
Carbone, Emily
Dittamore, Ryan
Scher, Howard I.
EUROPEAN UROLOGY, 2020, 77 (02) : 170 - 177
[29] Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide
Pal, Sumanta K.
He, Miaoling
Chen, Lin
Yang, Lixin
Pillai, Raju
Twardowski, Przemyslaw
Hsu, JoAnn
Kortylewski, Marcin
Jones, Jeremy O.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (04) : 162.e1 - 162.e6
[30] Circulating Tumor Cells in Diagnosis and Treatment of Lung Cancer
Maly, Vilem
Maly, Ondrej
Kolostova, Katarina
Bobek, Vladimir
IN VIVO, 2019, 33 (04): : 1027 - 1037

← 1 2 3 4 5 →